Ugur Sahin Sells 33,000 Shares of BioNTech (NASDAQ:BNTX) Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 33,000 shares of the business's stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $97.81, for a total value of $3,227,730.00. Following the transaction, the chief executive officer owned 456,209 shares of the company's stock, valued at approximately $44,621,802.29. This represents a 6.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

• 4 Reasons Pfizer Could Be a Value Play You Can't Miss

Ugur Sahin also recently made the following trade(s):

• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.

BioNTech Stock Up 2.9%

---

---

BioNTech stock opened at $100.87 on Wednesday. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00. The stock has a market cap of $25.51 billion, a price-to-earnings ratio of -12.88 and a beta of 1.29. The company's 50-day moving average price is $97.75 and its two-hundred day moving average price is $94.80. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01.

• Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company's revenue was down 59.5% on a year-over-year basis. During the same period in the prior year, the company posted ($1.60) earnings per share. On average, analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Trending Headlines about BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Berenberg raised its price target on BioNTech following the stock’s recent pullback, signaling improved potential upside and helping support the shares. Berenberg lifts BioNTech price target
• Positive Sentiment: BioNTech benefited from broader enthusiasm for mRNA-based cancer treatments after Moderna’s positive melanoma-related news drove gains across the sector. Investors may view BioNTech’s cancer pipeline as an important longer-term growth opportunity. Moderna, Merck and BioNTech sector reaction
• Neutral Sentiment: CEO Ugur Sahin sold a combined 79,000 BioNTech shares for approximately $7.86 million across September 21 and 22. Both transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which reduces their significance as a signal of current management expectations; Sahin still retained 410,209 shares after the sales. BioNTech SEC insider trading filing
• Negative Sentiment: BMO Capital Markets downgraded BioNTech and lowered its price target after the company reduced its 2027 guidance and suffered a clinical setback. The downgrade highlights near-term execution and pipeline risks, although the report questioned whether Wall Street may be undervaluing BioNTech’s cancer portfolio. BioNTech downgrade and cancer pipeline analysis

Institutional Inflows and Outflows

• Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?

Institutional investors have recently modified their holdings of the stock. Larson Financial Group LLC lifted its position in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company's stock valued at $26,000 after acquiring an additional 127 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of BioNTech during the second quarter worth $39,000. Caitong International Asset Management Co. Ltd raised its position in shares of BioNTech by 1,012.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company's stock worth $53,000 after purchasing an additional 506 shares during the period. Vestcor Inc purchased a new stake in shares of BioNTech during the fourth quarter valued at $153,000. Finally, Rockefeller Capital Management L.P. lifted its holdings in shares of BioNTech by 328.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company's stock valued at $177,000 after purchasing an additional 1,423 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of research reports. Citigroup decreased their price target on BioNTech from $130.00 to $125.00 and set a "buy" rating for the company in a research note on Wednesday, August 5th. Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. UBS Group restated a "buy" rating on shares of BioNTech in a report on Wednesday, September 16th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of BioNTech in a research note on Friday, June 5th. Finally, BMO Capital Markets lowered BioNTech from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $128.00 to $105.00 in a report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, BioNTech presently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Get Our Latest Stock Analysis on BioNTech

About BioNTech

(Get Free Report)

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.

Featured Articles

• Five stocks we like better than BioNTech
• Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
• Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
• AMD Chips Away at NVIDIA's AI Throne
• Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].